Basilard BioTech https://validator.w3.org/feed/docs/rss2.html Basilard BioTech featured in Yole Developement’s i-Micronews Basilard BioTech, Inc. announces a second $250K pre-seed investment (total now $500k) from Palo Alto based Vertical Venture Partners (VVP). Massively-Parallelized, Deterministic Mechanoporation for Intracellular Delivery <span style=color:#7a7a7a;>(Published on ACS Publications)</span> Basilard Biotech, Inc. announces the premiere of their new HD animation video introducing SoloPore™, their novel, IP protected, a disruptive technology platform for ex-vivo cell and gene delivery. Basilard BioTech mentioned in Nature Technology (June 2022) as one of a few companies at the forefront of nanoneedle technology Press Releases Celletto™ How Celletto™ Works Our History Publications Founder Focus: Brynley Lee, CEO & Founder of Basilard BioTech (Sunstone, September 2022) Employment Opportunities Building successful nanomedicine start-ups (Nature Nanotechnology, August 2022) Media Cell Therapy Home Our People Primary Care Investors News Our Technology Eye Care Our Better Transfection Performance Validation Modern Technology Certified Doctors Success of Treatments Our Intellectual Property Cardiology Orthopedic Medicine Dental Care Ophthalmology Body Care Neurology Gastroenterology Diabetes Pediatrics Hepatology Gynecology Eye Care Orthopedic Medicine Contact Dental Care Cardiology Basilard Biotech to Transform the Engineering of Cell-based Therapies Using Their Novel Nanomechanical Gene Delivery Technology <span style=color:#7a7a7a;>(Published on BioInformant)</span>